VivoSim Labs, Inc. (VIVS) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 112.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $112.00K | (m) | (m) |
| 2026-03-31 | (m) | $131.00K | $0.00 | (m) |
| 2025-12-31 | (m) | $142.00K | $0.00 | (m) |
| 2025-09-30 | (m) | $140.00K | $2.00K | (m) |
| 2025-06-30 | (m) | $142.00K | $3.00K | (m) |
| 2025-03-31 | (m) | $144.00K | $5.00K | (m) |
| 2024-12-31 | (m) | $122.00K | (m) | (m) |
| 2024-09-30 | (m) | $103.00K | (m) | (m) |
| 2024-06-30 | (m) | $73.00K | (m) | (m) |
| 2024-03-31 | (m) | $109.00K | (m) | (m) |
| 2023-12-31 | (m) | $242.00K | (m) | (m) |
| 2023-09-30 | (m) | $368.00K | (m) | (m) |
| 2023-06-30 | (m) | $445.00K | (m) | (m) |
| 2023-03-31 | (m) | $370.00K | (m) | (m) |
| 2022-12-31 | (m) | $1.71M | (m) | (m) |
| 2022-09-30 | (m) | $1.58M | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $1.50M | (m) | (m) |
| 2022-02-22 | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $0.00 | (m) | (m) |
| 2021-09-30 | (m) | $0.00 | (m) | (m) |
| 2021-03-31 | (m) | $0.00 | $0.00 | (m) |
| 2020-12-31 | (m) | $0.00 | $0.00 | (m) |
| 2020-09-30 | (m) | $298.00K | $13.00K | (m) |
| 2020-06-30 | (m) | $1.53M | $277.00K | (m) |
| 2020-03-31 | (m) | $2.20M | $328.00K | (m) |
| 2019-12-31 | (m) | $2.88M | $429.00K | (m) |
| 2019-09-30 | (m) | $3.36M | $552.00K | (m) |
| 2019-06-30 | (m) | $3.07M | $413.00K | (m) |
| 2019-03-31 | (m) | $3.09M | $482.00K | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $399.00K | (m) | (m) |
| 2014-06-30 | (m) | $372.00K | (m) | (m) |
| 2014-03-31 | (m) | $379.00K | (m) | (m) |
| 2013-12-31 | (m) | $479.00K | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $1.29M | (m) | (m) |
| 2012-12-31 | (m) | $1.20M | (m) | (m) |
| 2012-09-30 | (m) | $848.21K | (m) | (m) |
| 2012-06-30 | (m) | $380.65K | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $374.16K | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |